• Dr. Reddy's profit attributable to shareholders fell 36% year-over-year to INR 9.25 billion in the quarter ended September 30, 2026.
• Quarterly revenues declined year-over-year to INR 86.71 billion.
• Research and development expenses dropped 16% year-over-year to INR 5.24 billion, while selling, general and administrative expenses rose 6% to INR 28.08 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.